Literature DB >> 34904410

Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study.

Jin Wook Lee1,2, Eun Mi Song3, Sung-Ae Jung3, Sung Hoon Jung4, Kwang Woo Kim5, Seong-Joon Koh5, Hyun Jung Lee5, Seung Wook Hong2, Jin Hwa Park2, Sung Wook Hwang2, Dong-Hoon Yang2, Byong Duk Ye2, Jeong-Sik Byeon2, Seung-Jae Myung2, Suk-Kyun Yang2, Sang Hyoung Park6.   

Abstract

In 2020, the novel coronavirus disease 2019 (COVID-19) began to spread worldwide and remains an ongoing medical challenge. This case series reports on the clinical features and characteristics of patients with inflammatory bowel disease (IBD) and confirmed COVID-19 infection. From February 2020 to March 2021, nine patients with IBD had confirmed COVID-19 across four hospitals in Korea. The median age at COVID-19 diagnosis was 42 years. Six patients were male, and seven patients had ulcerative colitis (UC). No patients required oxygen therapy, intensive care unit hospitalizations, or died. The most common symptom was fever, and gastrointestinal (GI) symptoms developed as diarrhea in five patients with UC. Oral steroids were used to combat UC aggravation in two patients. In this case series of nine IBD patients diagnosed with COVID-19 in Korea, the clinical presentation was predominately a mild respiratory tract infection. Most patients with UC developed new GI symptoms including diarrhea.
© 2021 The Korean Academy of Medical Sciences.

Entities:  

Keywords:  COVID-19; Crohn's Disease; Inflammatory Bowel Disease; Ulcerative Colitis

Mesh:

Substances:

Year:  2021        PMID: 34904410      PMCID: PMC8668498          DOI: 10.3346/jkms.2021.36.e336

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  29 in total

1.  Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?

Authors:  Mohamed Attauabi; Jakob Seidelin; Johan Burisch
Journal:  Gut       Date:  2021-03-03       Impact factor: 23.059

2.  No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.

Authors:  Dana Lukin; Gabriela Funez-dePagnier; Svetlana Lima; Daniel Lai; Lucia Duenas-Bianchi; Waseem Ahmed; Vinita Jacob; Robert Battat; Ellen Scherl; Randy S Longman
Journal:  Clin Gastroenterol Hepatol       Date:  2021-06-05       Impact factor: 11.382

3.  SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California.

Authors:  John Gubatan; Steven Levitte; Tatiana Balabanis; Akshar Patel; Arpita Sharma; Aida Habtezion
Journal:  Gastroenterology       Date:  2020-05-07       Impact factor: 22.682

4.  Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.

Authors:  Cristina Bezzio; Simone Saibeni; Angela Variola; Mariangela Allocca; Alessandro Massari; Viviana Gerardi; Valentina Casini; Chiara Ricci; Fabiana Zingone; Arnaldo Amato; Flavio Caprioli; Marco Vincenzo Lenti; Chiara Viganò; Marta Ascolani; Fabrizio Bossa; Fabiana Castiglione; Claudio Cortelezzi; Laurino Grossi; Monica Milla; Daniela Morganti; Luca Pastorelli; Davide Giuseppe Ribaldone; Alessandro Sartini; Alessandra Soriano; Gianpiero Manes; Silvio Danese; Massimo Claudio Fantini; Alessandro Armuzzi; Marco Daperno; Gionata Fiorino
Journal:  Gut       Date:  2020-04-30       Impact factor: 23.059

5.  Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.

Authors:  Dana J Lukin; Anand Kumar; Kaveh Hajifathalian; Reem Z Sharaiha; Ellen J Scherl; Randy S Longman
Journal:  Gastroenterology       Date:  2020-05-29       Impact factor: 22.682

6.  Current new challenges in the management of ulcerative colitis.

Authors:  Tomohiro Fukuda; Makoto Naganuma; Takanori Kanai
Journal:  Intest Res       Date:  2019-01-25

7.  Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves.

Authors:  Rami M Elshazli; Adam Kline; Abdelaziz Elgaml; Mohamed H Aboutaleb; Mohamed M Salim; Mahmoud Omar; Ruhul Munshi; Nicholas Mankowski; Mohammad H Hussein; Abdallah S Attia; Eman A Toraih; Ahmad Settin; Mary Killackey; Manal S Fawzy; Emad Kandil
Journal:  J Med Virol       Date:  2021-02-23       Impact factor: 20.693

Review 8.  Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea.

Authors:  Ki Ho Hong; Sang Won Lee; Taek Soo Kim; Hee Jae Huh; Jaehyeon Lee; So Yeon Kim; Jae Sun Park; Gab Jeong Kim; Heungsup Sung; Kyoung Ho Roh; Jae Seok Kim; Hyun Soo Kim; Seung Tae Lee; Moon Woo Seong; Namhee Ryoo; Hyukmin Lee; Kye Chul Kwon; Cheon Kwon Yoo
Journal:  Ann Lab Med       Date:  2020-09       Impact factor: 3.464

9.  Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice.

Authors:  Yan Chen; Qiao Yu; Francis A Farraye; Gursimran S Kochhar; Charles N Bernstein; Udayakumar Navaneethan; Kaicun Wu; Jie Zhong; David A Schwartz; Hao Wu; Jing-Jing Zheng; Marietta Iacucci; Ravi P Kiran; Bo Shen
Journal:  Intest Res       Date:  2020-06-02

10.  Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Anupam K Singh; Anuraag Jena; Praveen Kumar-M; Daya Krishna Jha; Vishal Sharma
Journal:  Intest Res       Date:  2021-01-18
View more
  2 in total

1.  Impact of COVID-19 Pandemic on the Quality of Life of IBD Patients.

Authors:  Otilia Gavrilescu; Cristina Cijevschi Prelipcean; Mihaela Dranga; Iolanda Valentina Popa; Cătălina Mihai
Journal:  Medicina (Kaunas)       Date:  2022-04-19       Impact factor: 2.948

Review 2.  Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Long Chen; Kai Hu; Cheng Cheng; Quanman Hu; Liang Zhang; Tongyan An; Yongjun Guo; Shuaiyin Chen; Guangcai Duan
Journal:  Int J Colorectal Dis       Date:  2022-10-22       Impact factor: 2.796

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.